Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. MediWound Ltd.
  6. News
  7. Summary
    MDWD   IL0011316309

MEDIWOUND LTD.

(MDWD)
  Report
Delayed Quote. Delayed Nasdaq - 01/28 04:00:01 pm
2.23 USD   -1.76%
01/24Health Care Stocks Declining This Afternoon
MT
01/24Health Care Stocks Dragged Lower in Broad-Based Equities Selloff
MT
01/24Wall Street Set for Losses Amid Ukraine Crisis
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MediWound : Cowen Trims MediWound's Price Target to $6 From $7, Maintains Outperform Rating

06/29/2021 | 03:54pm EST


© MT Newswires 2021
All news about MEDIWOUND LTD.
01/24Health Care Stocks Declining This Afternoon
MT
01/24Health Care Stocks Dragged Lower in Broad-Based Equities Selloff
MT
01/24Wall Street Set for Losses Amid Ukraine Crisis
MT
01/24Health Care Stocks Retreat Premarket Monday
MT
01/24Top Premarket Gainers
MT
01/24MediWound Discloses 'Positive' Data From Phase 2 Study of Leg Ulcer Treatment
MT
01/24MEDIWOUND : Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for..
PU
01/24MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx fo..
GL
01/24Mediwound Announces Positive Topline Results from Its U.S. Phase 2 Trial of Escharex fo..
CI
2021MediWound Says Phase 2 Study of EscharEx Treatment for Chronic Wounds Delivers Positive..
MT
More news
Analyst Recommendations on MEDIWOUND LTD.
More recommendations
Financials (USD)
Sales 2021 23,9 M - -
Net income 2021 -13,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,55x
Yield 2021 -
Capitalization 60,8 M 60,8 M -
Capi. / Sales 2021 2,55x
Capi. / Sales 2022 2,39x
Nbr of Employees -
Free-Float 57,2%
Chart MEDIWOUND LTD.
Duration : Period :
MediWound Ltd. Technical Analysis Chart | MDWD | IL0011316309 | MarketScreener
Technical analysis trends MEDIWOUND LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 2,23 $
Average target price 6,92 $
Spread / Average Target 210%
EPS Revisions
Managers and Directors
Sharon Malka Chief Executive Officer
Boaz Gur-Lavie Chief Financial Officer
Stephen T. Wills Executive Chairman
Lior Rosenberg Chief Medical Officer
Ety Klinger Chief Research & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
MEDIWOUND LTD.-5.51%61
CSL LIMITED-11.42%86 224
SAMSUNG BIOLOGICS CO.,LTD.-18.16%40 428
ALEXION PHARMACEUTICALS, INC.0.00%40 336
WUXI BIOLOGICS (CAYMAN) INC.-19.72%40 175
BIOGEN INC.-6.13%33 082